Hemolytic-uremic syndrome medical therapy: Difference between revisions
m Categories |
|||
| Line 2: | Line 2: | ||
{{HUS}} | {{HUS}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
==Medical Therapy== | ==Medical Therapy== | ||
Treatment is generally supportive with [[dialysis]] as needed. [[Platelet]] [[blood transfusion|transfusion]] may actually worsen outcome. | Treatment is generally supportive with [[dialysis]] as needed. [[Platelet]] [[blood transfusion|transfusion]] may actually worsen outcome. | ||
| Line 18: | Line 20: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Nephrology]] | [[Category:Nephrology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
Revision as of 17:13, 17 June 2016
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome medical therapy |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
Treatment is generally supportive with dialysis as needed. Platelet transfusion may actually worsen outcome.
In severe cases or when there is diagnostic uncertainty between HUS and TTP, plasmapheresis is the treatment of choice.
Antibiotic treatment of O157:H7 colitis may stimulate further verotoxin production and thereby increase the risk of HUS.[1]
- Plasma exchange daily until LDH normal and platelets stable
- Renal pathology may not entirely resolve (no data on continued plasma exchange after platelets and markers of hemolysis have resolved)
- Average 7-16 exchanges required to induce remission
- Caution plasmapheresis-associated thrombocytopenia (more with certain instruments)
- Cryopoor plasma exchange not better than regular FFP